Big Pharma's Year of Big Layoffs
Executive Summary
It has been quite a year for pharmaceutical restructuring. But where are the cuts coming from? Here's a snapshot of the 40,000 or so layoffs from the industry's big players.
You may also be interested in...
Biopharma: Reviewing 2007 to Forecast 2008
If there's a theme to many of the top pharmaceutical stories of 2007 it's infrastructure: the crisis of owning too much infrastructure when R&D productivity is at its lowest level since 1983, and the economic power of leveraging someone else's. That's the connection, for example, between: Bristol-Myers "selective integration" strategy and its huge partnering deals with Pfizer and AstraZeneca; the rise of biopharma-focused private equity; the investment boom in China; the emerging strategies focused on reaping value from proof-of-concept development; even the now customary twin-tracking of the IPO/M&A process. Other key events for 2007 that will re-shape the playing field for 2008: the new role of CMS as a partner with FDA in the regulatory process; the continuing importance of large molecules and discovery platforms to Big Pharma; and the strategic restructuring of spec pharma.
Biopharma: Reviewing 2007 to Forecast 2008
If there's a theme to many of the top pharmaceutical stories of 2007 it's infrastructure: the crisis of owning too much infrastructure when R&D productivity is at its lowest level since 1983, and the economic power of leveraging someone else's. That's the connection, for example, between: Bristol-Myers "selective integration" strategy and its huge partnering deals with Pfizer and AstraZeneca; the rise of biopharma-focused private equity; the investment boom in China; the emerging strategies focused on reaping value from proof-of-concept development; even the now customary twin-tracking of the IPO/M&A process. Other key events for 2007 that will re-shape the playing field for 2008: the new role of CMS as a partner with FDA in the regulatory process; the continuing importance of large molecules and discovery platforms to Big Pharma; and the strategic restructuring of spec pharma.
Access and Evidence: Implications of the EPO Safety Debate (Part 2)
It looks like CMS is making its restrictive coverage policy on Aranesp and Procrit stick. That is a big hit to Amgen and J&J. It is also an important precedent for other manufacturers: CMS is demonstrating that it can deny coverage based on the absence of evidence-even when the therapy is the standard of care.